Teprotumumab-trbw (Tepezza)

Tepezza (teprotumumab‑trbw) is covered only for the FDA‑approved indication of thyroid eye disease (including Graves' ophthalmopathy/orbitopathy) in adults with active, at least moderate‑severity disease and is not covered for non‑FDA indications. Coverage requires age ≥18, prescription or consultation with an ophthalmologist/endocrinologist/thyroid‑eye specialist, documentation of diagnosis and active moderate‑severity signs (e.g., inflammation, proptosis, diplopia), verification the patient has not exceeded 8 doses per treated eye, a 6‑month authorization, and the recommended dosing of 10 mg/kg initial then 20 mg/kg every 3 weeks for seven additional infusions.

"Tepezza (teprotumumab-trbw) is indicated for the treatment of thyroid eye disease."

Sign up to see full coverage criteria, indications, and limitations.